tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-pyridin-2-ylcarbamate | 475059-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-pyridin-2-ylcarbamate
• 英文别名: tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridylcarbamate；tert-butyl N-[4-[(E)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyridin-2-yl]carbamate
• CAS: 475059-58-6
• 化学式: C₁₈H₂₃N₃O₂S
• 分子量: 345.466
• InChiKey: KJVGTKVEMQTPFQ-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-pyridin-2-ylcarbamate 在 盐酸 作用下， 生成 4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-aminopyridine
  参考文献：
  名称：

  MexAB-OprM-Specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization

  摘要：

  The identification of a series of compounds that specifically inhibit efflux by the MexAB-OprM pump system in Pseudomonas aeruginosa is described. Synthesis and in vitro structure-activity relationships (SARs) are outlined. Early leads lacked activity in animal models, and efforts to improve solubility and reduce serum protein binding by the introduction of polar groups are discussed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.024
• 作为产物：
  描述：

  4-异丙基-2-甲基噻唑 、 2-Boc-氨基-4-甲酰基吡啶 在 乙酸酐 作用下， 生成 tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-pyridin-2-ylcarbamate
  参考文献：
  名称：

  MexAB-OprM-Specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization

  摘要：

  The identification of a series of compounds that specifically inhibit efflux by the MexAB-OprM pump system in Pseudomonas aeruginosa is described. Synthesis and in vitro structure-activity relationships (SARs) are outlined. Early leads lacked activity in animal models, and efforts to improve solubility and reduce serum protein binding by the introduction of polar groups are discussed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.024

文献信息

• Drug efflux pump inhibitor
  申请人：DAIICHI PHARMACEUTICAL CO., LTD

  公开号：US20030092720A1

  公开（公告）日：2003-05-15

  A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): 1 wherein, R 1 and R 2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W 1 represents —CH═CH—, —CH 2 O—, —CH 2 CH 2 — or the like; R 3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R 4 represents hydrogen atom, a group of —OZ 0-4 R 5 (Z 0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R 5 represents a cyclic alkyl group, an aryl group or the like); W 2 represents a single bond or —C(R 8 )═C(R 9 )— (R 8 and R 9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W 2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

  一种用于预防和/或治疗微生物感染的药物，其活性成分表示为以下一般式(I)的化合物： 其中，R1和R2代表氢原子、卤素原子、羟基或类似物，W1代表—CH═CH—、—CH2O—、—CH2CH2—或类似物；R3代表氢原子、卤素原子、羟基或氨基；R4代表氢原子、—OZ0-4R5（Z0-4代表烷基链、氟取代的烷基链或单键，R5代表环烷基、芳基或类似物）；W2代表单键或—C(R8)═C(R9)—（R8和R9代表氢原子、卤素原子、较低烷基或类似物，Q代表酸性基团，但W2和Q可以共同形成乙烯基噻唑二酮或等效的杂环环；m和n代表0到2的整数，q代表0到3的整数。
• Medicine for inhibiting drug elimination pump
  申请人：Nakayama Kiyoshi

  公开号：US20050009843A1

  公开（公告）日：2005-01-13

  A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R 1 and R 2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W 1 represents —CH═CH—, —CH 2 O—, —CH 2 CH 2 — or the like; R 3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R 4 represents hydrogen atom, a group of —OZ 0-4 R 5 (Z 0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R 5 represents a cyclic alkyl group, an aryl group or the like); W 2 represents a single bond or —C(R 8 )═C(R 9 )—(R 8 and R 9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W 2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

  预防和/或治疗微生物感染的药物，其活性成分为以下通用式（I）所表示的化合物：其中，R1和R2表示氢原子、卤原子、羟基或类似物，W1表示—CH═CH—、—CH2O—、—CH2CH2—或类似物；R3表示氢原子、卤原子、羟基或氨基；R4表示氢原子、—OZ0-4R5（Z0-4表示烷基、氟代烷基或单键，R5表示环烷基、芳基或类似物）；W2表示单键或—C（R8）═C（R9）—（R8和R9表示氢原子、卤原子、低烷基或类似物，Q表示酸性基团，但W2和Q可以共同形成乙烯基噻唑烷二酮或等效的杂环环；m和n表示0至2的整数，q表示0至3的整数。
• MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1389463A1

  公开（公告）日：2004-02-18

  A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents -CH=CH-, -CH2O-, -CH2CH2- or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of -OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or -C(R8)=C(R9)- (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

  一种用于预防和/或治疗微生物感染的药物，其活性成分包括由以下通式(I)代表的化合物： 其中，R1 和 R2 代表氢原子、卤素原子、羟基或类似基团；W1 代表-CH=CH-、-CH2O-、-CH2CH2-或类似基团；R3 代表氢原子、卤素原子、羟基或氨基；R4 代表氢原子、-OZ0-4R5 的基团（Z0-4 代表亚烷基、氟取代的亚烷基或单键，R5 代表环状烷基、芳基或类似基团）；W2 代表单键或-C(R8)＝C(R9)-（R8 和 R9 代表氢原子、卤素原子、低级烷基或类似基团，Q 代表酸性基团，但 W2 和 Q 可共同形成亚乙烯基噻唑烷二酮或等效的杂环；m 和 n 代表 0 至 2 的整数，q 代表 0 至 3 的整数。
• US7056917B2
  申请人：——

  公开号：US7056917B2

  公开（公告）日：2006-06-06
• MexAB-OprM-Specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and early strategies for lead optimization
  作者：Kiyoshi Nakayama、Yohei Ishida、Masami Ohtsuka、Haruko Kawato、Ken-ichi Yoshida、Yoshihiro Yokomizo、Shigeru Hosono、Toshiharu Ohta、Kazuki Hoshino、Hiroko Ishida、Kumi Yoshida、Thomas E. Renau、Roger Léger、Jason Z. Zhang、Ving J. Lee、William J. Watkins

  DOI：10.1016/j.bmcl.2003.07.024

  日期：2003.12

  The identification of a series of compounds that specifically inhibit efflux by the MexAB-OprM pump system in Pseudomonas aeruginosa is described. Synthesis and in vitro structure-activity relationships (SARs) are outlined. Early leads lacked activity in animal models, and efforts to improve solubility and reduce serum protein binding by the introduction of polar groups are discussed. (C) 2003 Elsevier Ltd. All rights reserved.